IRIS Guide for Applicants - Updated Submission Requirements
MAHs and sponsors must register for an EMA account and appropriate role to submit via the IRIS platform, as this is a new requirement for all IRIS submissions.
Tag archive
MAHs and sponsors must register for an EMA account and appropriate role to submit via the IRIS platform, as this is a new requirement for all IRIS submissions.
Organizations must establish an active EMA user account, ensure they have a valid EMA customer account number, and complete the SPOR/OMS registration process within five to ten working days if not previously registered.
Ensure all relevant teams are prepared to transition to the mandatory SEND format for data submissions by the effective date of 15 June 2026.
Review and update data submission practices to align with the new technical specifications; ensure compliance with FDA-supported data standards.
Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.
MAHs and technical teams must review the revised API registration requirements and implement necessary system updates to comply by the established timelines.
Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.
Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.
MAHs should prepare for enhanced regulatory collaboration, including potential joint oversight activities and reduced market friction between the UK and US due to closer alignment in regulatory decisions.
Update internal labeling workflows to align with the revised checklist; ensure submission documents meet updated formatting requirements for linguistic review.
Review the consultation document and consider submitting feedback by 2026-07-31. Monitor for final regulatory changes affecting radiopharmaceutical safety monitoring and compliance.
Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.
Subscribe to impact-first pharmacovigilance updates. Select every role you want in your digest.
Digest roles: QPPV. Work email only